Voclosporin for Lupus Nephritis: A #NephJC Editorial on AURORA

Bourne Auguste, Jade Teakell, Avinash Rao Ullur, Joel M. Topf, and Swapnil Hiremath

#NephJC is a recurring Twitter-based journal club. #NephJC editorials highlight the discussed article and summarize key points from the NephJC TweetChat.

Introduction

Kidney involvement in systemic lupus erythematosus (SLE) is common with 40% to 70% of patients who develop some form of lupus nephritis. Approximately 6% to 19% of patients with lupus nephritis will develop end-stage kidney disease within a decade of an SLE diagnosis. Patients with lupus nephritis are usually treated with immunosuppressive therapy that may include a combination of glucocorticoids, mycophenolate mofetil (MMF), or cyclophosphamide. There have been several controlled clinical trials in lupus nephritis, with both biologic agents and conventional cytotoxic and antimetabolite medications. However, no drug has received formal US Food and Drug Administration approval for the treatment of lupus nephritis in the last decade. These agents continue to be used off-label, and have far-from-perfect response rates and considerable toxicities. For example, reduction in proteinuria within the first 6-12 months of initial treatment is recognized as an important prognostic marker for predicting disease flares, progression to end-stage kidney disease, and death. However, up to 60% of patients with lupus nephritis are unable to achieve guideline targets for proteinuria (urine protein-creatinine ratio (UPCR) < 0.5-0.7 mg/mg) within the first year of treatment with current therapeutic options. Belimumab, a recombinant human antibody that inhibits B-cell activating factor, was the first drug approved by the US Food and Drug Administration in 2011 for the treatment of SLE and has shown efficacy in lupus nephritis as well. Two trials have reported the efficacy of a calcineurin inhibitor (CNI), tacrolimus, which reduced proteinuria in patients with lupus nephritis. In light of this, voclosporin, a novel CNI initially developed for transplant recipients, has more recently pivoted for the management of lupus nephritis. Voclosporin is structurally similar to cyclosporine, except for one amino acid, and has a higher affinity for calcineurin binding along with more predictable pharmacokinetics. The phase 2 trial with voclosporin was AURA-LV (Aurinia Urinary Protein Reduction Active–Lupus With Voclosporin) which compared 2 voclosporin doses (23.7 mg and 39.5 mg twice a day) to placebo, on a background of steroids and MMF, to assess the efficacy and adverse events. There was an increase in complete response at 6 months for both doses, but only reaching statistical significance for the 23.7-mg dose. Serious adverse events occurred more often in both voclosporin groups, and more deaths occurred in the low-dose group compared to the placebo and high-dose voclosporin groups. This led to the current phase 3 trial, AURORA-1 (Aurinia Renal Response in Active Lupus With Voclosporin).

The Study

AURORA-1 was a phase 3 trial to verify the efficacy and safety of voclosporin (as an add-on to MMF and steroids) to treat lupus nephritis. It was a global, multicenter, double-blind, randomized, placebo-controlled trial with sites in 27 countries across North and South America, Africa, Asia, and Europe. Patients with SLE, a kidney biopsy showing lupus nephritis (class III, IV, V; alone or in combination), and evidence of active disease on the basis of proteinuria were included. Notable among the exclusion criteria was estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m². All patients received intravenous methylprednisolone for 2 days followed by a rapid oral prednisone taper, going down to 2.5 mg/day by week 16. They also received MMF up to 1 g twice a day. The intervention arm received 23.7 mg of voclosporin twice a day for 52 weeks (ie, 3 pills of 7.9 mg twice a day), and the control group received a matching placebo. The primary end point was a complete response at week 52, defined by UPCR ≤0.5 mg/mg, eGFR ≥60 mL/min, no need for rescue medications, and no more than 10 mg of prednisone per day in weeks 44-52. The secondary end points, analyzed hierarchically, included time to UPCR ≤0.5 mg/mg, partial response (UPCR reduction of ≥50%) at 24 or 52 weeks, and complete response at 24 weeks. The trial was powered for a 14.4% higher absolute increase in complete response rate (from 20% in placebo to 34.4% in voclosporin; odds ratio [OR], 2.1). The trial was funded by Aurinia Pharmaceuticals, the makers of voclosporin, who also collected, analyzed, and interpreted the data.

The trial successfully recruited 357 participants with lupus nephritis, of whom ~90% were women, including a mix of ethnicities, and the majority having normal eGFR and class IV lupus nephritis. A complete response was seen in 41% of patients treated with voclosporin compared to 23% of patients in the placebo group (OR, 2.65; 95% confidence interval [CI], 1.64-4.27; P < 0.0001). A difference in complete response at 24 weeks was also observed with 32% versus 20% of patients in the voclosporin versus the placebo group, respectively (OR, 2.23; 95% CI, 1.34-3.72;
Lastly, the voclosporin group had a shorter time to UPCR ≤ 0.5 mg/mg at 169 days compared to 372 days in the control group (hazard ratio, 2.02; 95% CI, 1.51-2.70; \( P < 0.001 \)). Given the well-preserved kidney function based on eligibility, it was not surprising to note that the mean eGFR was less than 5 mL/min/1.73 m\(^2\) different from baseline, with no difference between groups. The rate of adverse events (most commonly, infections) was the same in both groups, 91% and 89%, and deaths occurred in 1 patient in the voclosporin group (<1%) compared to 5 in the control group (3%). Interestingly, gastrointestinal and nervous system disorders were almost twice as common with voclosporin compared to placebo, in keeping with the CNI side effect profile.

### The Tweetchat

The NephJC tweetchat discussion about AURORA-1 on June 22 and 23, 2021, included 162 nephrologists, patients, and rheumatologists. The participants tweeted 1,045 times. At baseline, less than 5% of the participants said that they would use CNIs as the first choice for induction in lupus nephritis, despite prior data on CNIs in lupus, and only reserved CNIs for class V or refractory situations. Most of the discussion centered around the use of proteinuria reduction as the outcome of choice, because the effect of CNIs on proteinuria is already known, and 2 previous trials have demonstrated the effect of CNIs (tacrolimus) on this outcome.\(^{18,19}\) Though the lack of nephrotoxicity was reassuring, the follow-up of one year was thought to be short. It was also noted that the immunological parameters (eg, complement...
levels and antibodies) studied did not change significantly, though these are not reliable markers of disease activity in lupus nephritis. Some felt that a better comparator for voclosporin would have been another CNI (ie, cyclosporine or tacrolimus). The pricing plan, at $92,000 a year for voclosporin, produced severe sticker shock. Even with the advantage of avoiding therapeutic drug monitoring, this represents about 40 times the cost of tacrolimus, with no advantage of avoiding therapeutic drug monitoring, this maintenance dose was 10 mg. This also came with a reduction in steroid to 2.5 mg at week 16, as compared with the group members of the rapid taper regime used in the trial of steroid to 2.5 mg at week 16, as compared with the previous trials where the taper was usually slower, and the maintenance dose was 10 mg. This also came with a response rate in the placebo group of 20%, higher than usually seen in historical lupus nephritis trials.

Overall, less than 10% of the participants thought that they would use voclosporin in this setting, with a slightly higher preference to use another CNI and significant enthusiasm for the rapid steroid taper protocol (see Fig 1B for poll response). Voclosporin was a welcome addition to the therapeutic armamentarium but not considered to be a revolutionary addition. The discussants also had concerns about whether the increased number of medications, even at lower doses, incur more side effects (Fig 1C).

ARTICLE INFORMATION

Authors' Full Names and Academic Degrees: Bourne Auguste, MD, Jade Teakell, PhD, Avinash Rao Ullur, MD, Joel M. Topf, MD, and Swapnil Hirahemat, MPH

Authors' Affiliations: Department of Medicine, University of Toronto, Toronto, ON, Canada (BA, ARU); Department of Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX (JT); Department of Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI (JMT); Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada (SH).

Address for Correspondence: Swapnil Hirahemat, MPH, 1967 Riverside Dr, Ottawa, ON K1H7W9, Canada. Email: shiremah@toh.ca

Support: SH receives research salary support from the Department of Medicine, University of Ottawa.

Financial Disclosure: JT has an ownership stake in Da Vita run dialysis clinics and has served on the advisory boards of Takeda, Astra Zeneca, Tricida, and Bayer; the remaining authors declare that they have no relevant financial interests.

Other Disclosures: JT and SH serve on the board of NephJC as President and Vice-President, respectively. NephJC (www.nephjc.com) is a 503c organization that supports social media in medical education and has multiple industry and academic supporters. JT and SH receive no remuneration for these positions.

Peer Review: Received August 20, 2021, in response to an invitation from the journal. Evaluated by 1 external peer reviewer, with direct editorial input from the Editor-in-Chief. Accepted in revised form October 1, 2021.

Publication Information: © 2021 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Published online October 22, 2021 with doi 10.1016/j.xkme.2021.10.001

REFERENCES

1. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011;6(4): 330-336.
2. Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011-1020.
3. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131.
4. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112.
5. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-64.
6. Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083-2089.
7. Dooley MA, Jayne D, Ginzelr EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895.
8. Rovin BH, Furie R, Lahn T, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226.
9. Furie R, Nichols K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379-389.
10. Landmark nephrology. Landmark trials in lupus nephritis. January 9, 2019. Accessed August 19, 2021. https://landmarknephrology.com/topic/lupus-nephritis/
11. Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-1313.
12. Tamirou F, Lauwersys BR, Dell’Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1): e000123.
13. Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1(1):e00018.
14. Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32(8):1338-1344.
15. Navarra SV, Guzmán RM, Gallagher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.
16. Hitt E. Belimumab earns FDA approval for lupus. Medscape. March 10, 2011. Accessed July 19, 2021. https://www.medscape.com/viewarticle/738729.
17. Furie R, Rovin BH, Houssiau FA, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128.
18. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19(10):2001-2010.
19. Liu ZH, Zhang HT, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. *Ann Intern Med*. 2015;162(1):18-26.

20. Kuglstatter A, Mueller F, Kusznir E, et al. Structural basis for the cyclophilin A binding affinity and immunosuppressive potency of E-ISA247 (voclosporin). *Acta Crystallogr D Biol Crystallogr*. 2011;67(2):119-123.

21. Rovin BH, Solomons N, Pendergraft WF III, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. *Kidney Int*. 2019;95(1):219-231.

22. Harrison P. Patient benefits justify price of new lupus nephritis drugs. Medscape. April 26, 2021. Accessed July 19, 2021. https://www.medscape.com/viewarticle/949935.

23. De Rosa M, Rocha AS, De Rosa G, Dubinsky D, Almaani SJ, Rovin BH. Low-grade proteinuria does not exclude significant kidney injury in lupus nephritis. *Kidney Int Rep*. 2020;5(7):1066-1068.